218 related articles for article (PubMed ID: 35157254)
1. A Comprehensive Approach to Managing Methamphetamine-Associated Cardiomyopathy.
Osekowski M; Trytell A; La Gerche A; Prior D; MacIsaac A; Paratz ED
Am J Cardiovasc Drugs; 2022 Jul; 22(4):385-393. PubMed ID: 35157254
[TBL] [Abstract][Full Text] [Related]
2. Methamphetamine-associated cardiomyopathy.
Won S; Hong RA; Shohet RV; Seto TB; Parikh NI
Clin Cardiol; 2013 Dec; 36(12):737-42. PubMed ID: 24037954
[TBL] [Abstract][Full Text] [Related]
3. Poor outcomes in methamphetamine-associated cardiomyopathy-a growing health issue in New Zealand.
Wang TKM; Kueh SA; Sutton T; Gabriel R; Lund M; Looi JL
N Z Med J; 2019 Sep; 132(1502):55-66. PubMed ID: 31563927
[TBL] [Abstract][Full Text] [Related]
4. Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.
Thoi F; Scherer DJ; Kaye DM; Sanders P; Stokes MB
Heart Lung Circ; 2022 May; 31(5):616-622. PubMed ID: 35153149
[TBL] [Abstract][Full Text] [Related]
5. The Cardiac Complications of Methamphetamines.
Paratz ED; Cunningham NJ; MacIsaac AI
Heart Lung Circ; 2016 Apr; 25(4):325-32. PubMed ID: 26706652
[TBL] [Abstract][Full Text] [Related]
6. Methamphetamine-associated cardiomyopathy: an addiction medicine perspective.
Somma V; Osekowski M; Paratz E; Bonomo Y
Intern Med J; 2023 Jan; 53(1):21-26. PubMed ID: 36693638
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review.
Reddy PKV; Ng TMH; Oh EE; Moady G; Elkayam U
J Am Heart Assoc; 2020 Jun; 9(11):e016704. PubMed ID: 32468897
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine-Associated Congestive Heart Failure: Increasing Prevalence and Relationship of Clinical Outcomes to Continued Use or Abstinence.
Sliman S; Waalen J; Shaw D
Cardiovasc Toxicol; 2016 Oct; 16(4):381-9. PubMed ID: 26661075
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.
Sutter ME; Gaedigk A; Albertson TE; Southard J; Owen KP; Mills LD; Diercks DB
Clin Toxicol (Phila); 2013 Aug; 51(7):540-4. PubMed ID: 23855716
[TBL] [Abstract][Full Text] [Related]
10. Methamphetamine-Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities.
Dickson SD; Thomas IC; Bhatia HS; Nishimura M; Mahmud E; Tu XM; Lin T; Adler E; Greenberg B; Alshawabkeh L
J Am Heart Assoc; 2021 Aug; 10(16):e018370. PubMed ID: 34365802
[TBL] [Abstract][Full Text] [Related]
11. Acute Heart Failure in a 39-Year-Old Man.
Ashby D; Niblock F; Herring K; Mims L
Am Fam Physician; 2020 Jan; 101(2):117-118. PubMed ID: 31939641
[No Abstract] [Full Text] [Related]
12. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse.
Ito H; Yeo KK; Wijetunga M; Seto TB; Tay K; Schatz IJ
Clin Cardiol; 2009 Jun; 32(6):E18-22. PubMed ID: 19330818
[TBL] [Abstract][Full Text] [Related]
13. Prosthodontics treatment considerations for methamphetamine-dependent patients.
Gantos MA; Manzotti A; Yuan JC; Afshari FS; Marinis A; Syros G; Rynn MH; Sukotjo C
J Prosthodont; 2015 Jan; 24(1):64-70. PubMed ID: 25627552
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Clinical Characteristics and Outcomes of Patients With Reversible Versus Persistent Methamphetamine-Associated Cardiomyopathy.
Zhao SX; Seng S; Deluna A; Yu EC; Crawford MH
Am J Cardiol; 2020 Jan; 125(1):127-134. PubMed ID: 31699360
[TBL] [Abstract][Full Text] [Related]
15. Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module).
Diercks DB; Fonarow GC; Kirk JD; Jois-Bilowich P; Hollander JE; Weber JE; Wynne J; Mills RM; Yancy C; Peacock WF;
Am J Cardiol; 2008 Nov; 102(9):1216-9. PubMed ID: 18940295
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Methamphetamine-associated Cardiomyopathy and the Impact of Methamphetamine Use on Cardiac Dysfunction.
Reddy PK; Chau E; Patel SV; Yang K; Ng TM; Elkayam U
Am J Cardiol; 2021 Sep; 154():86-91. PubMed ID: 34233837
[TBL] [Abstract][Full Text] [Related]
17. Exposure to Amphetamines Leads to Development of Amphetamine Type Stimulants Associated Cardiomyopathy (ATSAC).
Jafari Giv M
Cardiovasc Toxicol; 2017 Jan; 17(1):13-24. PubMed ID: 27663745
[TBL] [Abstract][Full Text] [Related]
18. Methamphetamine psychosis: epidemiology and management.
Glasner-Edwards S; Mooney LJ
CNS Drugs; 2014 Dec; 28(12):1115-26. PubMed ID: 25373627
[TBL] [Abstract][Full Text] [Related]
19. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery.
Voskoboinik A; Ihle JF; Bloom JE; Kaye DM
Intern Med J; 2016 Jun; 46(6):723-7. PubMed ID: 26929061
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine abuse and "meth mouth".
Rhodus NL; Little JW
Northwest Dent; 2005; 84(5):29, 31, 33-7. PubMed ID: 16317979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
